Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00705640 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Advanced Melanoma
A Phase 1 study, sponsored by Craig L Slingluff, Jr.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT00705640 is a Phase 1 study that has completed, run by Craig L Slingluff, Jr. The registered enrollment target is 45 participants.
The verdict
NCT00705640, a Phase 1 study, has completed, sponsored by Craig L Slingluff, Jr.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
RATIONALE: Vaccine therapy may help the body build an effective immune response to kill tumor cells. PURPOSE: This randomized clinical trial is studying how well vaccine therapy works in treating patients with advanced melanoma.
Interventions
- PROCEDURE biopsy
- BIOLOGICAL incomplete Freund's adjuvant
- BIOLOGICAL multi-epitope melanoma peptide vaccine
- BIOLOGICAL tetanus toxoid helper peptide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2008-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00705640
The ClinicalTrials.gov registry entry for NCT00705640 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Craig L Slingluff, Jr, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which biopsy is the first listed.
NCT00705640 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00705640 about?
NCT00705640 is a clinical study titled "Vaccine Therapy in Treating Patients With Advanced Melanoma". RATIONALE: Vaccine therapy may help the body build an effective immune response to kill tumor cells. PURPOSE: This randomized clinical trial is studying how well vaccine therapy works in treating patients with advanced melanoma.
What is the current status of trial NCT00705640?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2008-05.
What interventions are being tested in trial NCT00705640?
The interventions under investigation include: biopsy (PROCEDURE), incomplete Freund's adjuvant (BIOLOGICAL), multi-epitope melanoma peptide vaccine (BIOLOGICAL), tetanus toxoid helper peptide (BIOLOGICAL).
Who is sponsoring clinical trial NCT00705640?
This trial is sponsored by Craig L Slingluff, Jr, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.